Author
University of HelsinkiORCID 0000-0001-6643-5216Unclaimed ORCID profile · follow to get notified of new preprints
6 papers
Recent·Most cited
Anna Pirttikoski, Shabnaz Koochakkhani, Laura Gall-Mas…·Anna Vähärautio
The paper identifies conserved cell states in ovarian high-grade serous carcinoma that correlate with poor prognosis and presents actionable targets for improving platinum response.
Laura Gall-Mas, Katrin Kleinmanns, Anna Pirttikoski…·Benno Schwikowski
The paper uses single-cell RNA sequencing to identify resistance signatures in ovarian cancer and develops a framework for combination therapy with carboplatin.
Johanna Eriksson, Shuyu Zheng, Mihaela Lucia Popa…·Jing Ping Tang
This study uses ReSisTrace to identify pre-sensitizing agents for FLT3 inhibitors in FLT3-ITD-positive AML by analyzing transcriptional signatures and validating compounds that enhance treatment efficacy.
Jie Bao, Sanna Pikkusaari, Jun Dai…·Jing Ping Tang
This study identifies BX-912 as a therapeutic agent for ovarian serous carcinoma, revealing HES1 as a target and showing synergistic effects with olaparib.
Kaiyang Zhang, Erdoğan Pekcan Erkan, Jun Dai…·Anna Vähärautio
The paper identifies a stress-related transcriptional profile in ovarian cancer linked to chemotherapy resistance and poor survival, suggesting MEK1/2 inhibitors as a potential treatment.
Antti Häkkinen, Kaiyang Zhang, Amjad Alkodsi…·Sampsa Hautaniemi
PRISM recovers cell type specific expression profiles from composite RNA-seq data, improving patient response prediction compared to raw bulk data.